Details

Autor(en) / Beteiligte

• Van Cutsem, Eric
• Köhne, Claus-Henning
• Hitre, Erika
• Zaluski, Jerzy
• Chang Chien, Chung-Rong
• Makhson, Anatoly
• D'Haens, Geert
• Pintér, Tamás
• Lim, Robert
• Bodoky, György
• Roh, Jae Kyung
• Folprecht, Gunnar
• Ruff, Paul
• Stroh, Christopher
• Tejpar, Sabine
• Schlichting, Michael
• Nippgen, Johannes
• Rougier, Philippe

Titel

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Ist Teil von

• The New England journal of medicine, 2009-04, Vol.360 (14), p.1408-1417

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2009

Quelle

MEDLINE

Beschreibungen/Notizen

• Previous trials have shown that the combination of fluorouracil-based chemotherapy and cetuximab is active when used as salvage treatment in patients with metastatic colorectal cancer; the present trial shows activity of this combination as first-line treatment as well. The trial also found that for cetuximab to be active, an unmutated KRAS gene in the tumor was required. This trial shows activity of the combination of fluorouracil-based chemotherapy and cetuximab as first-line treatment. The trial also found that for cetuximab to be active, an unmutated KRAS gene in the tumor was required. Colorectal cancer is the third most common cancer worldwide. 1 Approximately 25% of patients with colorectal cancer present with overt metastatic disease, and metastatic disease develops in 40 to 50% of newly diagnosed patients. Standard first-line treatments include fluorouracil with leucovorin and irinotecan 2 , 3 or oxaliplatin, 4 alone or combined with bevacizumab. 5 The immunoglobulin G1 monoclonal antibody against the epidermal growth factor receptor (EGFR), cetuximab (Erbitux), is effective in combination with irinotecan in patients with metastatic colorectal cancer or as a single agent in patients with metastatic colorectal cancer that progresses even when irinotecan is used. 6 , 7 Phase 1 and 2 studies . . .